U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H31ClN6O3.2ClH
Molecular Weight 523.884
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PPACK DIHYDROCHLORIDE

SMILES

Cl.Cl.N[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl

InChI

InChIKey=XKDCRQWZLPWLFG-LKLBIAKRSA-N
InChI=1S/C21H31ClN6O3.2ClH/c22-13-18(29)16(8-4-10-26-21(24)25)27-19(30)17-9-5-11-28(17)20(31)15(23)12-14-6-2-1-3-7-14;;/h1-3,6-7,15-17H,4-5,8-13,23H2,(H,27,30)(H4,24,25,26);2*1H/t15-,16+,17+;;/m1../s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C21H31ClN6O3
Molecular Weight 450.962
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

PPACK is a synthetic peptide that irreversibly inhibits thrombin-mediated platelet activation by binding to the active site of thrombin with a Ki = 0.24 nM. PPACK competes with alpha-thrombin at the high-affinity site and is an antagonist of alpha-thrombin induced activation. PPACK is used as a tool for assessment of Platelet function.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P00734|||Q9UCA1
Gene ID: 2147.0
Gene Symbol: F2
Target Organism: Homo sapiens (Human)
24.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone.
1988 May
Proton bridging in the interactions of thrombin with small inhibitors.
2009 Aug 4
Patents

Sample Use Guides

Vascular graft-bearing baboons (Papio anubis) were administered PPACK (100 nmol/kg per min) by continuous intravenous infusion. The treatment abolished platelet deposition, vascular graft occlusion, thrombus associated release of platelet-specific proteins and fibrino-peptides, platelet hemostatic plug formation, platelet aggregation and thrombin-induced blood clotting. The effects of PPACK disappeared within 15 min after the infusion was discontinued.
Route of Administration: Intravenous
In Vitro Use Guide
Platelet-rich plasma was incubated with 10 uM PPACK and the drug completely inhibited thrombin-induced platelet aggregation. The effect of PPACK on platelet deposition at the site of balloon injury was measured with 10 uM of the drug. Platelet deposition at the site of balloon injury was reduced by 47%.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:06:57 GMT 2023
Edited
by admin
on Fri Dec 15 16:06:57 GMT 2023
Record UNII
5K09050P7Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PPACK DIHYDROCHLORIDE
MI  
Common Name English
D-PHE-PRO-ARG-CHLOROMETHYL KETONE, DIHYDROCHLORIDE
Common Name English
L-PROLINAMIDE, D-PHENYLALANYL-N-((1S)-4-((AMINOIMINOMETHYL)AMINO)-1-(2-CHLOROACETYL)BUTYL)-, DIHYDROCHLORIDE
Systematic Name English
D-PHENYLALANYL-PROLYL-ARGININE CHLOROMETHYL KETONE DIHYDROCHLORIDE
Systematic Name English
PPACK DIHYDROCHLORIDE [MI]
Common Name English
FPRMECL, DIHYDROCHLORIDE
Common Name English
Code System Code Type Description
FDA UNII
5K09050P7Z
Created by admin on Fri Dec 15 16:06:57 GMT 2023 , Edited by admin on Fri Dec 15 16:06:57 GMT 2023
PRIMARY
MERCK INDEX
m9086
Created by admin on Fri Dec 15 16:06:57 GMT 2023 , Edited by admin on Fri Dec 15 16:06:57 GMT 2023
PRIMARY Merck Index
CAS
82188-90-7
Created by admin on Fri Dec 15 16:06:57 GMT 2023 , Edited by admin on Fri Dec 15 16:06:57 GMT 2023
PRIMARY
PUBCHEM
13042154
Created by admin on Fri Dec 15 16:06:57 GMT 2023 , Edited by admin on Fri Dec 15 16:06:57 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE